Last reviewed · How we verify
NCT06572085
Neuroprotective Effect of Butylphthalide for Cardiac Arrest Patients
Phase 4 trial testing Butylphthalide and Sodium Chloride Injection in Butylphthalide in 350 participants. Currently enrolling.
31 December 2027
Quick facts
| Lead sponsor | Tang Ziren |
|---|---|
| Phase | Phase 4 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 350 |
| Start date | 1 January 2022 |
| Primary completion | 31 December 2027 |
| Estimated completion | 31 December 2027 |
| Sites | 1 location across China |
Drugs / interventions tested
- Butylphthalide and Sodium Chloride Injection — full drug profile →
- Saline Solution
Conditions studied
- Butylphthalide — all drugs for Butylphthalide →
- Cardiac Arrest — all drugs for Cardiac Arrest →
- Neuroprotective Drugs — all drugs for Neuroprotective Drugs →
Sponsor
Tang Ziren — full company profile →
Who can join
Adults 18 to 80, any sex, with Butylphthalide or Cardiac Arrest. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Cardiac arrest is one of the critical illnesses that is directly life-threatening, and patients who survive cardiac arrest develop severe neurological deficits or even die. The effectiveness of drugs to improve neurological function in resuscitated brain-injured patients has been a focus of research in the field of resuscitation. Butanephthalein has an ameliorating effect on the damage of central nervous function in patients with acute ischemic stroke, and can promote the improvement of patients' neurological deficits. On this basis, the present study was designed as a multicenter, prospective randomized controlled experiment, with internationally accepted methods for assessing near-term and long-term neurological function, to determine the effectiveness of butalbital in improving neurological function after cardiac arrest, with the aim of searching for new methods and ideas to improve neurological function and prognosis after cardiac arrest.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06572085
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Butylphthalide and Sodium Chloride Injection
Trials testing the same drug.
- NCT06353334 — Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA · Phase 4 · recruiting
Other recruiting trials for Butylphthalide
Currently open trials in the same condition.
- NCT06353334 — Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA · Phase 4 · recruiting
Other Tang Ziren trials
Trials by the same sponsor.
- NCT06696690 — The Safety and Efficacy of Median Nerve Electrical Stimulation for Improving Neurological Function Prognosis in Patients · NA · not yet recruiting
- NCT06543849 — The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients · NA · active not recruiting
- NCT06575101 — Resting Energy Expenditure and Substrate Consumption in Cardiac Arrest Patients Under Target Temperature Management · recruiting
- NCT06624488 — The Relationship Between Brain Injury Biomarkers in Cerebrospinal Fluid and Blood of Patients After Cardiac Arrest and P · recruiting
- NCT06353334 — Butylphthalide's Safety and Efficacy for Improving Neurological Function Prognosis in Patients With Cardiac Arrest (BNCA · Phase 4 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06572085 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tang Ziren
- Last refreshed: 11 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06572085.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing